An evergreen fund established by a family office in Asia is operating from a committed capital of USD 300 million. The fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The fund likes to lead investments in local-based businesses and co-invest in businesses overseas. The fund is currently focused on new opportunities in Greater China and Southeast Asia, while they are also interested in US, Canada, and EU-based companies with a China angle.
Currently, the firm is interested in cutting edge, innovative therapeutic and platform technologies in cancer, CNS, and chronic diseases. The fund considers all stages from preclinical through pre-IPO. The fund also considers a broad range of technologies including medical devices, diagnostics, healthcare services, and nutraceuticals. In medical devices, the fund is open to all indications and prefers later stage projects with proof of concept.
The firm is looking for competent, experienced, and reliable management teams when considering investment. Prior to deciding on allocations, the fund’s management team typically spends months interacting with candidate companies to determine their track record, quality of scientific research, technical expertise, and flexibility and reliability in working with investors. The fund prefers to work with Greater China-based companies or foreign businesses that are seeking to enter the Greater China market. The fund typically requires a board seat in the companies it invests in.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org